Caribou Biosciences reported that a single dose of their off-the-shelf CB-011 CAR-T cell therapy produced deep and durable responses in heavily pretreated, BCMA-naïve patients with relapsed or refractory multiple myeloma (r/r MM). In a phase 1 trial, 83% of patients achieved complete response, with 91% showing minimal residual disease negativity and half maintaining this response at 15 months. A case study also showed effectiveness in a patient previously treated with another CAR-T therapy. The therapy demonstrated a manageable safety profile and is expected to report further dose expansion data in the second half of 2026. This highlights CB-011's potential to provide accessible, effective treatment for patients with limited options.
Indonesia Energy Corporation's President Frank Ingriselli will present an update on the drilling of the K-29 well at the Kruh Block during the Planet MicroCap Conference on June 17, 2026. The company has commenced pre-drilling operations and remains ...
Four artificial intelligence companies are planning to raise more capital than the entire U.S. IPO market has raised over the past five years. This highlights the massive investor interest and growth potential in the AI sector. However, investors are...
OPTA VIA, a coach-guided metabolic health program by Medifast, demonstrated significant clinical results in a 16-week randomized controlled trial. Participants lost 14% visceral fat and retained 98% of lean mass, verified by DXA body composition scan...
Medifast highlights that declining estrogen during perimenopause leads to increased visceral fat and muscle loss, which typical weight loss programs often overlook. Their OPTA VIA program focuses on reducing visceral fat while preserving lean muscle,...
Uklon, a popular Ukrainian ride-hailing app owned by VEON Ltd., has launched Uklon Store, its first in-app marketplace, beginning with flower delivery services in Kyiv. This new feature allows users to order flowers from local florists and have them ...
